Galapagos to transfer drug discovery and research activities in Romainville, France to NovAliX, a drug-discovery focused Contract Research Organization (...
With its resplendent flowers, the Madagascar periwinkle plant (Catharanthus roseus) easily draws attention to itself, both in a natural setting and in ...
CABA-201 data package and experience from prior autoimmune cell therapy INDs informed Phase 1/2 clinical trial design, including the initial dose to be eva...
Today, NEC and NOI announced that NOI will be realigned as a subsidiary of NEC Bio B.V. (NB) in Hilversum, Netherlands, a newly established wholly owned su...
Patients with inflammatory diseases being treated with therapeutic monoclonal antibodies (mAbs) such as Infliximab may experience a significant increase in...
TandemAI today announced the release of TandemViz™ 1.0, the company’s proprietary web-based platform that provides its growing roster of drug d...
Sanofi (India) announced that it has received marketing authorization for its diabetes drug Soliqua™ (in pre-...
Merck KGaA, Darmstadt, Germany regains exclusive worldwide rights to develop, manufacture and commercialize BAVENCIO from Pfizer Deal is the latest exam...
Patients treated suffered from platinum resistant/refractory ovarian cancer Previous PD-(L)1/CTLA-4 combinations have reported only 3-10% re...
ncyte (Nasdaq:INCY) announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Pemazyre® (pemigatinib), a selective fi...
HANSIZHUANG (serplulimab) is the first anti-PD-1 mAb for the first-line treatment of small cell lung cancer (SCLC) The EC and the FDA previously granted...
CancerVAX, Inc., developer of a breakthrough universal cancer vaccine that will use the body’s immune system to fight cancer, today announced that it...
The U.S. Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) for Jardiance® (empagliflozin) tablets, which ...
As part of the transaction, certain operational obligations of the parties related to GS-1811, an anti-CCR8 antibody, set forth in the license agreement ha...
© 2024 Biopharma Boardroom. All Rights Reserved.
